Activin receptor-like kinase 1 ligand trap reduces microvascular density and improves chemotherapy efficiency to various solid tumors

Clinical Cancer Research

Volumn 22, Issue 1, 2016, Pages 96-106

  Hawinkels, Lukas J A C ^a   De Vinuesa, Amaya Garcia ^a   Paauwe, Madelon ^a   Kruithof De Julio, Marianna ^a   Wiercinska, Eliza ^a,e   Pardali, Evangelia ^a,f   Mezzanotte, Laura ^a   Keereweer, Stijn ^a   Braumuller, Tanya M ^b   Heijkants, Renier C ^a   Jonkers, Jos ^b   Lowik, Clemens W ^a   Goumans, Marie José ^a   Ten Hagen, Timo L ^c   Ten Dijke, Peter ^a,d  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d UPPSALA UNIVERSITY   (Sweden)

^e GOETHE UNIVERSITY   (Germany)

^f UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVIN RECEPTOR LIKE KINASE 1 LIGAND TRAP; ANTINEOPLASTIC AGENT; BONE MORPHOGENETIC PROTEIN 9; CISPLATIN; DOXORUBICIN; MONOCLONAL ANTIBODY DC101; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; ACTIVIN RECEPTOR 2; ACVRL1 PROTEIN, HUMAN; ALK1-FC FUSION PROTEIN, HUMAN; HYBRID PROTEIN; IMMUNOGLOBULIN FC FRAGMENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER INHIBITION; CONTROLLED STUDY; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; HYPOXIA; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MELANOMA; MONOTHERAPY; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT; TUMOR VOLUME; ANIMAL; DISEASE MODEL; DRUG POTENTIATION; GENETICS; KNOCKOUT MOUSE; METABOLISM; NEOPLASMS; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; TUMOR CELL LINE;

ACTIVIN RECEPTORS, TYPE II; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; GROWTH DIFFERENTIATION FACTOR 2; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; MICE; MICE, KNOCKOUT; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; RECOMBINANT FUSION PROTEINS; TRANSFORMING GROWTH FACTOR BETA1; TUMOR BURDEN;

EID: 84954510787     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-0743     Document Type: Article

References (44)

1. Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2002;2:727-39.
2. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000;407:249-57.
3. Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011;473:298-307.
4. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989;246:1306-9.
5. Crawford Y, Ferrara N. Tumor and stromal pathways mediating refractoriness/resistance to anti-angiogenic therapies. Trends Pharmacol Sci 2009;30:624-30.
6. Mountzios G, Pentheroudakis G, Carmeliet P. Bevacizumab and micrometastases: revisiting the preclinical and clinical rollercoaster. Pharmacol Ther 2014;141:117-24.
7. Kieran MW, Kalluri R, Cho YJ. The VEGF pathway in cancer and disease: responses, resistance, and the path forward. Cold Spring Harb Perspect Med 2012;2:a006593.
8. Bergers G, HanahanD. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008;8:592-603.
9. Bhatt RS, Atkins MB. Molecular pathways: can activin-like kinase pathway inhibition enhance the limited efficacy of VEGF inhibitors?Clin Cancer Res 2014;20:2838-45.
10. Limaverde-Sousa G, Sternberg C, Ferreira CG. Antiangiogenesis beyond VEGF inhibition: A journey from antiangiogenic single-target to broadspectrum agents. Cancer Treat Rev 2013;40:548-57.
11. Carmeliet P, Jain RK. Principles andmechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov 2011;10:417-27.
12. Kristensen TB, Knutsson ML, Wehland M, Laursen BE, Grimm D, Warnke E, et al. Anti-vascular endothelial growth factor therapy in breast cancer. Int J Mol Sci 2014;15:23024-41.
13. Hawinkels LJ, Garcia de Vinuesa A, ten Dijke P. Activin receptor-like kinase 1 as a target for anti-angiogenesis therapy. Expert Opin Investig Drugs 2013;22:1371-83.
14. Cunha SI, Pietras K. ALK1 as an emerging target for antiangiogenic therapy of cancer. Blood 2011;117:6999-7006.
15. Scharpfenecker M, van Dinther M, Liu Z, van Bezooijen RL, Zhao Q, Pukac L, et al. BMP-9 signals via ALK1 and inhibits bFGF-induced endothelial cell proliferation and VEGF-stimulated angiogenesis. J Cell Sci 2007;120:964-72.
16. David L, Mallet C, Mazerbourg S, Feige JJ, Bailly S. Identification of BMP9 and BMP10 as functional activators of the orphan activin receptor-like kinase 1 (ALK1) in endothelial cells. Blood 2007;109:1953-61.
17. Cunha S, Pardali E, Thorikay M, Anderberg C, Hawinkels LJ, Goumans MJ, et al. Genetic and pharmacological targeting of activin receptor-like kinase 1 impairs tumor growth and angiogenesis. J Exp Med 2010;207:85-100.
18. Yoshimatsu Y, Lee YG, Akatsu Y, Taguchi L, Suzuki HI, Cunha SI, et al. Bone morphogenetic protein-9 inhibits lymphatic vessel formation via activin receptor-like kinase 1 during development and cancer progression. Proc Natl Acad Sci U S A 2013;110:18940-5.
19. Ricard N, Ciais D, Levet S, Subileau M, Mallet C, Zimmers TA, et al. BMP9 and BMP10 are critical for postnatal retinal vascular remodeling. Blood 2012;119:6162-71.
20. Mitchell D, Pobre EG, Mulivor AW, Grinberg AV, Castonguay R, Monnell TE, et al. ALK1-Fc inhibits multiple mediators of angiogenesis and suppresses tumor growth. Mol Cancer Ther 2010;9:379-88.
21. Bendell JC, Gordon MS, Hurwitz HI, Jones SF, Mendelson DS, Blobe GC, et al. Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of dalantercept, an activin receptor-like kinase-1 ligand trap, in Patients with advanced cancer. Clin Cancer Res 2014;20:480-9.
22. Derksen PW, Liu X, Saridin F, van der GH, Zevenhoven J, Evers B, et al. Somatic inactivation of E-cadherin and p53 in mice leads to metastatic lobular mammary carcinoma through induction of anoikis resistance and angiogenesis. Cancer Cell 2006;10:437-49.
23. VanDriel PB, van der Vorst JR, Verbeek FP, Oliveira S, Snoeks TJ, Keereweer S, et al. Intraoperative fluorescence delineation of head and neck cancer with a fluorescent anti-epidermal growth factor receptor nanobody. Int J Cancer 2014;134:2663-73.
24. Seynhaeve AL, Hoving S, Schipper D, Vermeulen CE, deWiel-Ambagtsheer GA, van Tiel ST, et al. Tumor necrosis factor α mediates homogeneous distribution of liposomes in murinemelanoma that contributes to a better tumor response. Cancer Res 2007;67:9455-62.
25. Li L, Ten Hagen TL, Haeri A, Soullie T, Scholten C, Seynhaeve AL, et al. A novel two-step mild hyperthermia for advanced liposomal chemotherapy. J Control Release 2014;174:202-8.
26. Keereweer S, Mol IM, Kerrebijn JD, Van Driel PB, Xie B, Baatenburg de Jong RJ, et al. Targeting integrins and enhanced permeability and retention (EPR) effect for optical imaging of oral cancer. J Surg Oncol 2012;105:714-8.
27. Hawinkels LJ, Paauwe M, Verspaget HW, Wiercinska E, van der Zon JM, van der Ploeg K, et al. Interactionwith coloncancer cells hyperactivates TGF-βbeta signaling in cancer-associated fibroblasts. Oncogene 2014;33:97-107.
28. Sanchez-Duffhues G, Garcia de Vinuesa A, Lindeman JH, Mulder-Stapel A, DeRuiter MC, van Munsteren C, et al. SLUG is expressed in endothelial cells lacking primary cilia to promote cellular calcification. Arterioscler Thromb Vasc Biol 2015;35:616-27.
29. Van Baardewijk LJ, Van der Ende J, Lissenberg-Thunnissen S, Romijn LM, Hawinkels LJ, Sier CF, et al. Circulating bonemorphogenetic protein levels and delayed fracture healing. Int Orthop 2013;37:523-7.
30. Hawinkels LJ, Verspaget HW, van Duijn W, van der Zon JM, Zuidwijk K, Kubben FJ, et al. Tissue level, activation and cellular localisation of TGF-β1 and association with survival in gastric cancer patients. Br J Cancer 2007;97:398-404.
31. Hawinkels L, Verspaget HW, van der Reijden JJ, Van der Zon J, Verheijen JH, Hommes D, et al. Active TGF-β1 correlates with myofibroblasts and malignancy in the colorectal adenoma-carcinoma sequence. Cancer Sci 2009;100:663-70.
32. David L, Mallet C, Keramidas M, Lamande N, Gasc JM, Dupuis-Girod S, et al. Bone morphogenetic protein-9 is a circulating vascular quiescence factor. Circ Res 2008;102:914-22.
33. Witte L, Hicklin DJ, Zhu Z, Pytowski B, Kotanides H, Rockwell P, et al. Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an antiangiogenic therapeutic strategy. Cancer Metastasis Rev 1998;17:155-61.
34. Jain RK. Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia. Cancer Cell 2014;26:605-22.
35. Suzuki Y, Ohga N, Morishita Y, Hida K, Miyazono K, Watabe T. BMP-9 induces proliferation of multiple types of endothelial cells in vitro and in vivo. J Cell Sci 2010;123:1684-92.
36. Hu-Lowe DD, Chen E, Zhang L, Watson KD, Mancuso P, Lappin P, et al. Targeting activin receptor-like kinase 1 inhibits angiogenesis and tumorigenesis through a mechanism of action complementary to anti-VEGF therapies. Cancer Res 2011;71:1362-73.
37. Cunha SI, Bocci M, Lovrot J, Eleftheriou N, Roswall P, Cordero E, et al. Endothelial ALK1 is a therapeutic target to block metastatic dissemination of breast cancer. Cancer Res 2015;75:2445-56.
38. Lee AH, Dublin EA, Bobrow LG, Poulsom R. Invasive lobular and invasive ductal carcinoma of the breast show distinct patterns of vascular endothelial growth factor expression and angiogenesis. J Pathol 1998;185:394-401.
39. Kerr G, Sheldon H, Chaikuad A, Alfano I, von DF, Bullock AN, et al. A small molecule targeting ALK1 prevents Notch cooperativity and inhibits functional angiogenesis. Angiogenesis 2015;18:209-17.
40. Jalota-Badhwar A, Bhatia D, Boreddy SR, Joshi A, Venkatraman M, Desai N, et al. P7170: a novel molecule with unique profile of mTORC1/C2 and Activin Receptor-Like Kinase 1 inhibition leading to anti-tumor and antiangiogenic activity. Mol Cancer Ther 2015;14:1095-106.
41. van Meeteren LA, Thorikay M, Bergqvist S, Pardali E, Stampino CG, Hu-Lowe D, et al. Anti-human activin receptor-like kinase 1 (ALK1) antibody attenuates bonemorphogenetic protein 9 (BMP9)-induced ALK1 signaling and interferes with endothelial cell sprouting. J Biol Chem 2012;287: 18551-61.
42. Necchi A, Giannatempo P, Mariani L, Fare E, Raggi D, Pennati M, et al. PF-03446962, a fully-human monoclonal antibody against transforming growth-factor-β (TGFβ) receptor ALK1, in pre-treated patients with urothelial cancer: an open label, single-group, phase 2 trial. Invest New Drugs 2014;32:555-60.
43. Goumans MJ, Valdimarsdottir G, Itoh S, Lebrin F, Larsson J, Mummery C, et al. Activin receptor-like kinase (ALK)1 is an antagonistic mediator of lateral TGFβ/ALK5 signaling. Mol Cell 2003;12:817-28.
44. Gupta S, Gill D, Pal SK, Agarwal N. Activin receptor inhibitors-dalantercept. Curr Oncol Rep 2015;17:441.